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The characterization of novel and reactive Phase I metabolites of 
xenobiotics, such as those frequently produced by P450 enzymes, is an area of 
interest that has led to increased research efforts during preclinical drug-testing 
and development. A key interest is improving our understanding of factors that 
contribute to competing Phase I reaction mechanisms, some of which produce 
stable products that can be further metabolized and excreted, and others that 
produce reactive metabolites capable of causing toxicities.  Due to the high-
energy nature of the P450 catalytic oxyferryl heme species, Compound I, P450 
enzymes can also catalyze different oxidation reaction mechanisms, including 
dehydrogenation reactions. Dehydrogenation reactions are more difficult to 
predict than the more common P450 oxygenation and dealkylation reactions. 
Moreover, dehydrogenation mechanisms can compete with hydroxylation 
mechanisms to produce unstable desaturated electrophilic metabolites capable 
of forming potentially toxic biomolecular adducts. The work presented here 
focuses on improving existing computational tools for the prediction of P450 
metabolism of two model substrates, raloxifene and 4-hydroxy-tamoxifen. These 
two compounds are FDA-approved selective estrogen receptor modulators 
currently used in the treatment of breast cancer. In Chapter 2 the development, 
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testing and refinement of molecular mechanics parameters for key species of the 
heme prosthetic group during the P450 catalytic cycle is presented. It is shown 
that the assignment of atomic partial charges for key heme species improves the 
identification of the sites of metabolism of raloxifene by CYP3A4. Building on this 
work, in Chapter 3 it is shown that despite using these new heme parameters, 
extensive quantum mechanics calculations to probe substrate reactivity,  
molecular dynamics of the enzyme structure to find representative active site 
conformations makes the greatest improvement in the identification of the sites of 
metabolism for 4-hydroxy-tamoxifen. In summary, this work identifies that heme 
electrostatics and enzyme conformational dynamics play important roles in 
enzyme function and that the ability to predict sites of metabolism for P450-
substrates requires the integration of both for the improvement of future in silico 
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 The application and refinement of calculations and mathematical models 
are central to the discipline of science. These calculations and models provide us 
with mental constructs that allow us to determine how well we understand the 
principles that govern the system we have chosen to study. In so doing, they also 
allow us to move from an observatory role to a more predictive role in our 
scientific endeavors. This distinction between roles of observation and 
classification, and analysis and prediction has separated the fields of classical 
physics, biology and chemistry throughout much of their history. However, with 
the complexity of the problems that are challenging modern research, and the 
vast array of sophisticated instrumentation and analytical methods available, 
present day researchers find themselves having to bridge these schisms and 
forge new interdisciplinary approaches.  
In this spirit, the work presented in this dissertation shows the application, 
development and refinement of computational tools used currently in biophysical 
chemistry research, to a problem of biomedical relevance in the field of drug 
metabolism and toxicology: the contribution of electrostatic and thermodynamic 
factors to competing reaction mechanisms during the enzymatic metabolism of 
therapeutic drugs. The relevance of the problem investigated is that the 
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metabolites formed from competing reaction mechanisms can differentiate 
between the safe elimination of compounds, and the production of toxicities. 
Currently, these toxicities are identified experimentally by measuring the 
propensity of different novel compounds to form covalent with biological 
molecules[1, 2]. This type of screening occurs late during the preclinical phase of 
drug-development and can result in lead compound failure, projects being 
abandoned or costly attempts made to redesign the compounds[3-5]. 
Computational tools are used throughout the drug-design process to help reduce 
development costs and timelines[6]. It is therefore obvious that improvements in 
the accuracy of substrate and enzyme models, as well as the tools used to 
predict their interactions, can be of enormous benefit. Thus, the long-term goal of 
this work is to improve drug design and safety with the hope of a beneficial 
impact on human health.  
The biological focus of this work is the human hepatic cytochrome P450 
enzymes that are involved in the metabolism of the majority of drugs in use 
today, CYP3A4. This enzyme is capable of metabolizing a variety of potentially 
toxic compounds with diverse chemical structures via numerous high-energy 
reaction mechanisms to facilitate their elimination[7]. Even though some of these 
reaction mechanisms are well understood, the factors that favor certain 
competing reaction mechanisms are not[8-10]. The challenge presented by this 
type of problem is well suited for the application of computational models. The 
structural basis of enzyme-substrate interactions and catalysis can be 
experimentally difficult, if not impossible, to measure. Computational tools based 
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on quantum or classical mechanics can help in understanding these details at an 
electronic or atomic level. Although these tools have limitations[11], they can 
prove useful adjuncts to more traditional experiments. Thus, an integrated use of 
theory and experiment could therefore aid in the identification of shortcomings of 
the theoretical tools within a scaffold of empirical data derived from well-
established experimental methodologies. Moreover, the refined use of the 
theoretical tools can provide models to help guide experiments. This work 
therefore exploits a unique opportunity for an interdisciplinary approach to apply, 
refine and develop new theoretical methodologies to increase the understanding 





















Overview of Classic Phases of Drug Metabolism 
 The metabolism and elimination of exogenous compounds is classically 
divided into three phases: Phase 1 activation reactions, Phase 2 conjugation 
reactions and Phase 3 transport and elimination1. Phase 1 reactions involve the 
“activation” of stable or unreactive atomic centers or bonds. These activation 
reactions can proceed via single or double electron oxidation reactions, and are 
commonly catalyzed by enzymes with highly energetic active sites, such as 
cytochrome P450 enzymes (CYP) and flavin monooxygenases. Cytochrome 
P450s require coenzyme reductase partners for the transfer of electrons, 
molecular oxygen and involve complex catalytic cycles2. P450 catalyzed 
reactions include hydroxylation and heteroatom dealkylation reactions, and 
provide a functional heteroatom for subsequent conjugation reactions. Phase 2 
reactions involve the conjugation of endogenous polar nucleophilic molecules to 
Phase 1 activated atomic centers. These reactions increase the solubility of 
these lipophilic substrates and expedite their elimination. Phase 2 reactions are 
also catalyzed by enzymes, such as glutathione-S-transferases, and also require 
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cofactors such as glutathione. These conjugation reactions typically involve the 
incorporation of a lipophilic substrate and a hydrophilic cofactor into one product 
molecule with increased water solubility. Phase 3 reactions involve transport 
molecules such as ATP-cassette binding transporters that require an energy 
source to transport molecules against their concentration gradients across 
membranes into the kidney tubules or bile canaliculi3. 
 From this rudimentary overview, it can be easily envisaged that the 
metabolism of drugs occurs through a complex interplay of different enzymes 
and cofactors.  One of the most studied central players in this complex scheme is 
the family of hepatic P450 enzymes which are involved in the Phase 1 
metabolism of the majority of drugs in use today. Since their discovery and 
characterization by Omura and Sato over 40 years ago4-7 this family of enzymes 
and their heme-containing active sites have remained the focus of constant 
research. The identification of the different classes of hepatic P450s which 
exhibit significant differences in substrate selectivity and metabolism has 
contributed enormously to increased drug safety8. 
 
The Structure-Function Relationship of Hepatic P450 Enzymes 
and the Potential Contribution of  Active-site 
 Plasticity in Substrate Selectivity 
 
P450 enzymes were first discovered as membrane-bound heme-
containing proteins, identified as colored pigments from rabbit livers that 
demonstrated a unique light absorption characteristic at the unusually long 
wavelength of 450 nm in the presence of carbon monoxide4-7,9. Due to this 
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physical property, this class of enzymes became known as cytochrome P450s, 
cyto- meaning from the cell, -chrome, meaning a color. Since their first discovery, 
P450 enzymes have been identified as important biological catalysts that are 
found within almost all phyla of life10 where they play key roles in many different 
biosynthetic and metabolic pathways, including the highly specific modifications 
of steroid and lipid molecules via numerous oxidation reaction mechanisms11.  
Hepatic cytochrome P450s demonstrate a degree of promiscuity in 
substrate selectivity typically not observed in P450s expressed in other cell 
types. This promiscuity in substrate recognition and the diversity of reaction 
mechanisms favors the role of these enzymes in protecting an organism with 
changing nutritional and environmental needs and conditions from the toxic build-
up of chemically and structurally diverse endogenous and exogenous 
compounds12. However, this very promiscuity in substrate selectivity, and the 
diversity in competing chemical reaction mechanisms, poses one of the most 
significant hurdles in the prediction of site and mechanism of the metabolism of 
novel compounds13,14. 
The basis for the diversity of chemical reaction mechanisms catalyzed by 
P450 enzymes has been investigated using a vast array of experimental 
approaches9. These methods include site-directed mutagenesis of the enzyme in 
substrate-recognition sequences first identified by Gotoh15, the use of UV-vis 
spectroscopy to identify changes in the oxidation state of the heme within the 
P450 active site16,17, radical-clock and kinetic isotope studies18 and mechanism-
based inhibition studies19,20. However, the direct elucidation of the structure of 
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human hepatic P450s has been hampered by their membrane association, an 
obstacle which posed a significant hurdle to modern spectroscopic studies. 
The elucidation of the three-dimensional structures of nonmembrane 
associated soluble bacterial P45021 allowed structure-based methods to be 
pursued for the elucidation of the basis for substrate selectivity and drug 
metabolism. Homology models of many human hepatic P450 were constructed 
based on sequence similarity to these  structures to investigate human drug 
metabolism9. However, these efforts produced mixed results and lacked 
significant predictive power for the metabolism of even the more substrate 
selective hepatic P450s, such as CYP2D622.  
Since the turn of the century, advances in recombinant expression 
technologies and x-ray crystallography have permitted elucidation of an ever 
increasing number of P450 structures, including engineered mammalian P450s 
missing the transmembrane region23-29. These advances have facilitated the 
expression, crystallization and x-ray spectroscopic analysis of one P450 that is 
responsible for the majority of oxidative drug metabolism in humans: CYP3A4. In 
fact, x-ray crystallography of CYP3A4 in the presence of novel substrates is 
attempted routinely during drug development to provide insights into substrate 
binding and sites of metabolism (SOM)30. However, a number of factors that 
include crystallization artifacts, absence or ambiguity of x-ray electron density 
within the P450 active site and the complexity of the P450s catalytic cycle limit 
the utility of x-ray crystallographic structural data to consistently answer most 
questions on P450 metabolism.  
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The growing body of x-ray crystallographic-based structural information on 
engineered mammalian microsomal P45031 has provided a great deal of insight 
into the potential structural dynamics of some of these enzymes31. For a few of 
the major human hepatic drug metabolizing enzymes, a number of different x-ray 
structures have been solved. For CYP3A4, there are seven published structures 
(PDB ID: 1TQN32, 1WOE33, 1WOF33, 1WOG33, 2VOM29, 2JOD29 and 3NXU34). 
Four (1TQN, 1W0E, 1W0F and 1W0G) are in a similar ‘closed’ state, the 1TQN 
structure has the highest resolution, the 1W0E, 1WOF and 1WOG are similar to 
one another and the 1TQN structure, but 1W0F and 1W0G have different 
molecules bound to them, a substrate progesterone and an inhibitor metyrapone, 
respectively. The more recent 2JOD, 2VOM and 3NXU structures demonstrate 
the potential plasticity of the active site of this enzyme when bound to either the 
substrate erythromycin, the inhibitor ritonavir or two molecules of the inhibitor 
ketoconazole, respectively29.  
The available x-ray structures have provided a great deal of information 
about differences in the structures of P450 enzymes, including the potential 
plasticity of these enzymes. However, the structural data from these x-ray studies 
provide us only with snap-shots of enzyme structures. Furthermore, the 
experimentally derived models may possess structural artifacts introduced by the 
crystallography conditions that may not be indicative of conformational plasticity 
that is of physiological relevance. The presence of these artifacts may be difficult 
to identify35, especially when only one or a few structure(s) exist for the P450-
substrate or -ligand binding mode of interest. Any unrecognized structural 
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artifacts could introduce significant errors in current structure-based methods that 
use these experimental models to understand the metabolism of other 
compounds35.  
The process of enzymatic catalysis is highly complex, involving substrate 
ingress and egress, complex electronic bond-breaking and bond–making 
processes and for CYP3A4, can involve intricate and distal interactions with 
multiple substrate molecules29, cofactors and the lipid membrane36. However, 
one improvement that can be directly addressed with current computational tools 
and models is the evaluation of the contribution of electrostatic and 
thermodynamic factors to existing x-ray structures, and the potential impact of 
those structural changes on enzyme-substrate interactions.  
 
The Role of the Heme Prosthetic Group in  
P450-Catalyzed Chemical Reactions 
 
The accurate prediction of metabolism of hepatic P450 enzymes is not 
only complicated by their promiscuity in substrate selectivity and conformational 
plasticity but also by the diversity in oxidation reactions they catalyze. Oxidation 
reactions, such as oxygenation reactions that are catalyzed by P450, are defined 
as either the loss of electrons or an increase in the oxidation state of the 
molecule or atom. P450 “hydroxylation” reactions are the prototypical Phase 1 
activation reaction catalyzed via P450 oxidation and involve the incorporation of 
one atom of oxygen from molecular oxygen into a hydrocarbon bond 9. However, 
P450s are capable of catalyzing a number of diverse chemical reactions37  and 
all of the observed reaction mechanisms are classifiable as oxidation reactions 9. 
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Since these enzymes can catalyze a number of high-energy reaction 
mechanisms other than incorporation of oxygen into a hydrocarbon bond, they 
are more accurately referred to as mixed-function oxidases38. The diversity in 
reaction mechanisms is made possible by the heme prosthetic group present in 
the P450 active site which facilitates controlled electron transfers and is 
responsible for their unique light absorbance characteristics that led to their 
discovery39.  
Heme prosthetic groups are specialized protein cofactors that incorporate 
porphyrin rings interacting with various metals, ligands and protein side chains.  
In the case of P450, this is an iron center which is coordinated to a sulfur atom in 
a cysteine residue.  The catalytically competent high valence oxyferryl heme 
species, Compound I, produced within the active site during the catalytic cycle 
has recently been directly observed40. Even though the electronic changes to the 
heme within the P450 active site during ligand binding and substrate turnover 
have been extensively studied experimentally, the development of a consistent 
set of transferable parameters for computational modeling of key species of the 
heme that form during the P450 catalytic cycle has faced significant challenges. 
One of the major difficulties is the open-shell states of this iron-containing 
prosthetic group that requires complicated quantum mechanics-based methods 
to accurately describe. However, even though it is commonly accepted that 
changes in the electronic state of the heme play an important role during P450-
catalysis, current models do not account for these changes in a consistent 
manner. Thus, an obvious improvement for computational approaches for the 
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prediction of P450-metabolism is the development and testing of a consistent 
and transferable set of parameters for the key heme species formed during the 
P450-catalytic cycle.  
 
P450-Catalyzed Dehydrogenation Reactions 
The heme prosthetic group provides the capacity for P450s to catalyze a 
number of high-energy reactions. Many of these reaction mechanisms lead to the 
safe elimination of numerous compounds. However, some reactions produce 
reactive metabolites. Identifying compounds that form reactive metabolites 
continues to be a major area of concern in the evaluation of the safety of new 
drugs41. In 2002, the FDA in collaboration with industry released official 
guidelines for the evaluation of the metabolites in safety testing during drug 
development42. Within these FDA MIST guidelines, it is stated: “Based on the 
nature of the chemical reactions involved, metabolites formed from Phase I 
reactions are more likely to be chemically reactive or pharmacologically active 
and, therefore, more likely to need safety evaluation”42. Thus, elucidating the 
factors that contribute to the formation of reactive metabolites via P450-catalyzed 
reactions, such as dehydrogenation continues to be of concern in drug safety 
and development. 
Experimental studies of have shown that a variety of commonly used 
pharmaceutical compounds43,44, natural products45-47 and environmental 
contaminants 48-50can produce reactive desaturated metabolites via P450-
catalyzed dehydrogenation reactions. The data from these studies indicate that a 
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variety of substrates can undergo dehydrogenation reactions to produce a variety 
of unstable metabolites including quinone methides51. Unfortunately, no clear set 
of rules has yet been established to predict accurately the dehydrogenation of 
substrates during P450-mediated metabolism. Unlike some of the better 
understood reaction mechanisms with distinctly different SOM, dehydrogenation 
and oxygenations can compete at the same SOM of a substrate52.  
Using gas-phase quantum mechanics based calculations, a study by 
Shaik and coworkers of radical clock substrates investigated the factors that 
contribute to the hydroxylation versus desaturation of trans-2-phenyl-iso-
propylcyclopropane 53. This was a follow-up study to an earlier theoretical 
investigation by the same investigators of the rebound mechanism originally 
proposed by Groves and coworkers54. This earlier study used gas-phase 
quantum mechanics based calculations with models of experimental radical clock 
substrates, and a truncated iron-porphine model with a thiolate ligand 
representation of the heme to provide insights into the mechanism of P450-
hydroxylation. These theoretical studies produced results in good agreement with 
experimental isotope-labeling and substrate-rearrangement data. The application 
of theory provided a scientific means to explain experimental results at a level 
that was not possible to do so with experiment alone, and validated the rebound 
mechanism proposed by Groves and coworkers, and the theoretical two-state 
reactivity and the gas-phase model system54. The follow-up study that focused 
on desaturation of the radical clock substrate used a similar model system and 
showed that the desaturation reaction mechanism can proceed spontaneously, 
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and is energetically more favorable under specific conditions than radical 
rebound38. These results required extrapolation from gas-phase calculations 
using truncated models to predict the factors that contribute to competing 
oxygenation versus dehydrogenation reactions during P450-mediated turnover of 
pharmaceutical compounds. The authors concluded that: “In sum: the oxidase-
dehydrogenase mixed activity occurs from the cationic intermediate species and 
requires electro-steric inhibition of the rebound process53.” Thus, to validate this 
hypothesis and to improve the currently available tools for predicting drug 
metabolism, an ideal experimental approach would use the biomedically relevant 
P450, e.g.  CYP3A4 and therapeutic compounds that are metabolized via 
competing hydroxylation and dehydrogenation reactions. 
 
Raloxifene and 4-Hydroxy-Tamoxifen are Useful Molecular  
Probes of P450 Enzyme-Substrate Interactions 
 
Raloxifene 
 Raloxifene is an FDA-approved selective estrogen receptor modulator 
used in the treatment of breast cancer55. CYP3A4 has been shown to both 
hydroxylate and dehydrogenate this compound in a regioselective manner56. 
Specifically, CYP3A4-mediated hydroxylation of raloxifene produces 3’-hydroxy-
raloxifene, and dehydrogenation putatively produces a di-quinone metabolite that 
is so unstable that it has only been observed as a nucleophile-conjugate57, 
shown in Figure 1.1. This di-quinone is believed to be the species responsible for 
the mechanism–based inactivation of CYP3A4 by raloxifene58,59. Recent work by 
our lab has shown that molecular modeling of CYP3A4 and raloxifene 
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interactions was greatly improved by the assignment of a preliminary set of 
atomic partial charges, and allowed the identification of Phe215 as playing an 
important role in determining hydroxylation versus dehydrogenation60. Since it 
has thus been experimentally validated that models based on raloxifene and 
CYP3A4 were improved by the assignment of partial charges representative of 
one state of the heme, this model system may be appropriate for the 
development and refinement of a set of consistent and transferable heme 




4-Hydroxy-tamoxifen (4OHT), is a primary metabolite of tamoxifen 
(TAMX), which is also an FDA-approved selective estrogen receptor modulator 
used extensively in the treatment of breast cancer 61. A number of P450 
metabolites of TAMX, 4-hydroxy-tamoxifen (4OHT), endoxifen and Metabolite E, 
an oxidative metabolite found abundantly in the plasma of TAMX-treated 
patients, have been shown to bind the estrogen receptor (ER) with a much higher 
affinity than the parent compound62-65. TAMX is thus classified as prodrug, 
requiring specific P450-mediated modifications to produce pharmacologically 
active metabolites required to achieve the desired therapeutic effect. P450-
mediated TAMX metabolism has been shown to be P450 specific66. A number of 
the metabolites, including 4OHT, also undergo P450 metabolism to form reactive 
secondary metabolites67, via both hydroxylation and dehydrogenation reactions. 
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P450-catalyzed dehydrogenation of 4OHT to quinone methide products can 
result in the formation of covalent adducts with other biomolecules in a 
nonenzymatic manner. A scheme of TAMX metabolism from parent to 4OHT, 
4OHT-quinone methide and a biomolecular adduct is shown in Figure 1.2. 4OHT 
is therefore a useful second molecular probe since it is a pharmacologically 
active drug metabolite that undergoes P450-mediated metabolism to form 
reactive products that pose a risk of toxicity, as is of concern in the MIST 
guidelines68. Furthermore, 4OHT poses a greater challenge to molecular 
modeling compared to raloxifene because it undergoes competing hydroxylation 
and dehydrogenation reactions at the same site of metabolism67. Thus, 4OHT 
can either validate the findings with raloxifene or provide insights into other 
mechanistic details of the determinants of P450-hydroxylation versus P450-
dehydrogenation reactions for alternative types of substrates. 
 
Development of Tools with Greater Predictive Power 
Within the fields of physical and biophysical chemistry, a number of well-
established computational approaches based on physical principles exist that 
can be used to provide insight into possible enzyme–substrate interactions. The 
computational tools that are currently available and applicable to enzyme-
substrate interactions and catalysis can be broadly separated into quantum 
mechanics based methods for understanding complex electronic configurations 
and behavior in smaller model systems and molecular mechanics based 
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methods that allow modeling and sampling of much larger systems such as 
proteins.  
Quantum mechanics calculations address the electronic structure of 
atoms and molecules, and can do so by representing the constituent electrons in 
an explicit manner. To accurately describe the quantum behavior of subatomic 
species, such as electrons, requires computationally expensive and sophisticated 
mathematics. Excellent and comprehensive reviews of this material may be 
found elsewhere69. Thus, even though quantum theory provides a useful 
approach for deriving properties based on the electronic structure of molecules, it 
is currently computationally too expensive to do so at the required level of theory, 
with a system that includes the entire P450.  
Molecular mechanics based methods are an atom-based treatment of 
molecular models and include sophisticated potential energy functions and 
parameter sets. Molecular mechanics based methods include docking programs 
and molecular dynamics simulations (MD). Docking calculations allow the 
modeling of interactions between biological macromolecules and inhibitor or 
substrate molecules. MD simulations allow modeling of thermodynamic factors 
within molecular models at an atomic level. The potential energy functions of the 
modern MD simulations have provided many useful insights into structure-
function relationships even though still suffering from some shortcomings70. 
Combinations of quantum mechanics and molecular mechanics methods 
have also been applied specifically to P450-catalysis based on experimentally 
derived structures. This work has been performed to date for only one P450, the 
14 
 
bacterial P450cam, for which multiple structures of key steps have been solved 
during the catalytic cycle with its substrate, camphor. This study has validated 
the application of mixed quantum mechanics and molecular mechanics 
(QM/MM)-based methodologies to evaluate both the electronic and structural 
factors involved in enzymatic catalysis and reaction mechanism for this bacterial 
P450. However, this type of approach also remains computationally too 
expensive for routine screening of chemical libraries. 
The work presented in this dissertation is a combined empirical and 
theoretical investigation of in silico tools to predict the site of metabolism of two 
therapeutic drugs known to be metabolized to reactive electrophiles via both 
oxygenation and dehydrogenation reactions by CYP3A4. Standard in vitro 
incubation techniques coupled with mass spectroscopic analysis of products are 
utilized to determine differences in metabolism of model substrates, raloxifene 
and 4OHT. This experimental approach is then integrated with a computational 
analysis of the contributions of electronic changes in the heme prosthetic group 
during the P450 catalytic cycle, and contributions of thermodynamic entropy-
driven processes to P450 structure and to enzyme-substrate. It is the ultimate 
goal of this research to improve the accuracy and reliability of computationally 
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QUANTUM MECHANICALLY DERIVED AMBER-COMPATIBLE 
HEME PARAMETERS FOR VARIOUS STATES OF THE 
CYTOCHROME P450 CATALYTIC CYCLE 
 
This chapter was reproduced with permission from the published paper from 
Shahrokh, K. Orendt, A. Yost, Garold S. and Cheatham III, T.E. The Journal of 



















































CONFORMATIONAL DYNAMICS OF CYP3A4 IMPLICATE THE 
IMPORTANT ROLE OF ARG212 COUPLED WITH THE  
OPENING OF INGRESS, EGRESS AND SOLVENT 




Structural red-flags for P450 substrates are commonly used during drug 
development to identify sites of metabolism (SOM) that have the potential to 
produce high-energy toxic metabolites. P450-catalyzed dehydrogenation 
reactions involve the abstraction of two hydrogen atoms from two different SOM 
and can produce unstable reactive products. 4-hydroxy-tamoxifen (4OHT) is the 
active metabolite of tamoxifen, a commonly used anticancer drug, which can 
undergo competing hydroxylation and dehydrogenation reactions during its 
turnover by CYP3A4. Ab initio gas-phase electronic structural characterization of 
4OHT identifies the sequence of hydrogen atom abstraction for dehydrogenation 
to an electrophilic quinone methide. To provide representative conformational 
sampling of CYP3A4, molecular dynamics (MD) simulations were applied along 
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multiple trajectories of the existing structure (PDB ID: 1TQN) to generate multiple 
templates of CYP3A4. Docking with both x-ray and MD-refined CYP3A4 
structures incorporating QM-based penta- and hexa-coordinate heme 
parameters identifies binding modes that are supportive of the observed 
metabolism of 4OHT by CYP3A4, including dehydrogenation. Our models 
indicate that coupled structural contributions of the ingress, egress and solvent 
channels to the CYP3A4 active site geometries play key roles in the observed 
4OHT binding modes. The models supporting dehydrogenation are 
experimentally validated and consistent with results from in vitro incubations of 
4OHT with wild type CYP3A4 and the site-directed point mutant CYP3A4 R212A. 
 
Introduction 
Cytochrome P450 enzymes (P450) metabolize a diverse set of substrates 
via different oxidation reaction mechanisms1,2.  As more and more experimental 
P450 structures with and without substrates become available3-5, the emerging 
consensus is that the extent of promiscuity in P450 substrate selectivity has a 
structural basis which relates to both the varied enzyme active site architectures 
and their plasticity6. These characteristics vary greatly between the different 
subfamilies of hepatic P4507-9. While hepatic P450 promiscuity in substrate-
selectivity favors the elimination of numerous endogenous and exogenous 
substrates whose accumulation can prove toxic to the organism10,  it presents a 
significant challenge to structure-based drug design. This promiscuity makes it 
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difficult to a priori predict if a putative lead compound will be adversely 
metabolized by P450s11,12.  
The characterization of novel and reactive Phase I drug metabolites, such 
as those produced by P450, is an area of increasing research efforts during 
preclinical drug-testing and development to help identify reactive metabolites13-15. 
Of key interest is improving our understanding of factors that contribute to 
competing Phase I reaction mechanisms, some of which produce stable products 
that can be further metabolized and/or excreted and others that produce reactive 
metabolites capable of inducing toxicities16.  Due to the high-energy nature of the 
catalytic oxyferryl species, Compound I17, P450s can catalyze a variety of 
different reaction mechanisms, such as dehydrogenation reactions, that can 
produce desaturated electrophilic metabolites capable of forming potentially toxic 
biomolecular adducts18,19. Although a number of tools exist to predict P450 
metabolism, they demonstrate a mixed level of success depending on the class 
of substrate, P450 and reaction mechanism. Since P450 can catalyze a number 
of different oxidation reactions, including competing reaction mechanisms at the 
same site of metabolism (SOM), simply identifying the major metabolite is not 
adequate for drug safety screening.  
Computational tools for predicting the site and mechanism of P450-
metabolism are commonly used to provide structural alerts for a given set of lead 
compounds11, the goal of which is to highlight and identify the potential for the 
generation of toxic metabolites early in the drug-design process. Ultimately, 
eliminating potentially reactive lead compounds earlier may reduce drug 
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development costs and timelines13,14,20. However, due to the diversity of the 
active site architecture and plasticity of the different subfamilies of hepatic P450, 
structure-based computational methods face a serious challenge in accurately 
predicting the SOM and the P450-catalyzed reaction mechanism (PRM), 
especially for CYP3A4 which is the hepatic P450 responsible for the majority of 
Phase I drug metabolism. Experimental data have demonstrated that CYP3A4 
can accommodate a wide variety of structurally diverse ligands, substrates, and 
cofactors8,21,22. The currently available x-ray structures of CYP3A4 (PDB ID: 
1W0E23, 1W0F23, 1W0G23, 1TQN24, 2J0D8, 2V0M8 and 3NXU25) support that this 
enzyme has a large plastic active site and suggests that the conformational 
dynamics of the CYP3A4 active site may have a direct impact on drug 
metabolism by influencing both the substrate selectivity and the specific reaction 
mechanism. 
Our group has focused on dehydrogenation reactions due to their potential 
to metabolize substrates to reactive metabolites. Dehydrogenation reactions are 
more difficult to predict than standard P450 reactions and moreover, they can 
compete with hydroxylation mechanisms. Predicting them is made even more 
complicated since dehydrogenation may involve the abstraction of two hydrogen 
atoms from two different SOM, in contrast to the conventional ‘text-book’ rebound 
mechanism for hydroxylation which only involves one SOM26. Although 
dehydrogenation reactions are not as well studied as other P450-catalyzed 
reactions, mechanistic studies reveal the requirement for the formation of a 
stable cationic species and suggest that the enzyme active-site - substrate 
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interactions impose steric hindrance within the P450 active site so as to inhibit 
the rebound process to form a hydroxylated product27. To our knowledge, 
currently tools do not yet exist for predicting the susceptibility of substrates to be 
dehydrogenated and to form electrophilic products. 
 In previous work, we showed that molecular modeling combined with 
docking methods were able to assess enzyme-substrate interactions important in 
the P450-metabolism of raloxifene (RALX) by CYP3A428. It was shown that the 
reliable prediction of enzyme-substrate interactions was greatly improved by the 
assignment of an initial set of chemically reasonable atomic partial charges for 
the resting high-spin ferric state of the heme. These theoretical studies correctly 
identified the SOM and were able to guide us to experimentally confirm the role 
of Phe215 in determining the selectivity of dehydrogenation versus oxygenation 
metabolic pathways. More recently, we have improved our heme models through 
the development of consistent and AMBER-compatible heme parameters for a 
number of heme states during the P450 catalytic cycle, including several penta-
coordinate and hexa-coordinate states with dioxygen and the catalytically 
activated oxygen atom bound, Compound I29. We validated these molecular 
mechanics parameters for the modeling of P450-substrate interactions with 
raloxifene and CYP3A428. With the new heme parameters, we were able to 
generate models that further improved our prediction of the SOM through a 
structure-based modeling approach. 
Building on the previous work, here we investigate the P450 metabolism 
of 4-hydroxy-tamoxifen (4OHT) which, similar to raloxifene, undergoes both 
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hydroxylation and dehydrogenation reactions30-32. 4OHT is a primary metabolite 
of tamoxifen (TAMX), which is a FDA-approved selective estrogen receptor 
modulator (SERM) used extensively in the treatment of breast cancer 33 (Figure 
3.1). 4OHT is a useful molecular probe since it is a pharmacologically active drug 
metabolite that can undergo P450-oxygenation and dehydrogenation to form 
reactive products, which is of concern in the MIST guidelines. Moreover, its 
metabolism is well understood and shown to be dependent on differences in the 
P450-subclass active sites30. Also, 4OHT provides an additional challenge for 
improving P450 models since unlike raloxifene, initiation of dehydrogenation 
reactions competes with hydroxylation reactions at the same SOM. To extend 
upon our previous approach, we use extensive quantum mechanics calculations 
to probe substrate reactivity for dehydrogenation, and molecular dynamics 
simulations to find representative enzyme active-site conformations (of the 1TQN 
PDB structure). With the incorporation of the recently published heme 
parameters29, these CYP3A4 MD –refined structures provide models for the 
docking experiments that incorporate thermodynamic fluctuations of enzyme 
structure and changes in the electronic state of the heme. 
We investigate if gas-phase quantum calculations at the HF/6-31G* and 
B3LYP/6-31G* level of the substrate structure can identify the dehydrogenation 
SOM and sequence of hydrogen abstraction. In addition to the gas-phase 
analysis, since experimental data indicate that P450 structure and dynamics may 
play a key role in metabolism, we have applied molecular dynamics (MD) 
methods to full P450 models in an attempt to better model enzyme-substrate 
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interactions. We used clustering analysis to produce representative structures 
from multiple MD trajectories, modified these MD-refined CYP3A4 structures with 
new heme parameters for a number of different steps of the P450 catalytic cycle 
and performed docking with the QM-optimized 4OHT structures. Our results 
indicate that including representative conformational sampling of enzyme and 
substrate configurations along with the use of penta- and hexa-coordinate QM-
based heme parameters for docking leads to an improved signal-to-noise for 
identifying the binding modes that are supportive of the entire observed 
metabolism of 4OHT by CYP3A4. These models are experimentally validated in 
line with our previous work with in vitro incubations of 4OHT with wild type 
CYP3A4 and the site-directed point mutant CYP3A4 R212A. 
  
Materials and Methods 
Computational 
All calculations were performed on the SGI Pople machine at the Pittsburgh 
Supercomputing Center and at the University of Utah’s Center for High 
Performance Computing. The calculations involved ab initio QM, homology 
modeling, current state-of-the-art MD simulations with current force fields and 
explicit solvent, and molecular docking. 
Substrate optimizations. All QM calculations were performed using 
Gaussian 03 software34 in the gas-phase. All structures were built, calculations 
set up, and results analyzed using Gaussview35. Initial conformations of 4OHT 
were intuitively organized to arrange the central ring system in one of two 
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propeller conformations while the other functional groups were arranged to 
sample the conformational space as completely as possible. These starting 
structures were all optimized at the HF/6-31G* level of theory. Overlay of 
optimized structures using UCSF Chimera was used to identify redundant 
structures which were not used for further refinement. All optimized structures 
were also subjected to frequency analysis at the same level of theory as the 
optimization. All species with an amine moiety had optimizations for multiple 
minima performed with both 0 and +1 formal charges.  
Dihedral scans. Scans of all ψ angles defined in Figure 3.2 were 
performed at the HF/6-31G* level of theory using one of the two lowest energy 
conformations of 4OHT, conformation A with a neutral charge. For ψETHYL, 
additional scans were also performed at the B3LYP/6-31G* and MP2/6-31G* 
levels of theory. 
Substrate bond stretching scans. Since relaxed scans produced non-
physical re-association of the abstracted hydrogen atom with some other portion 
of the molecule, rigid scans of the three bonds involved in the dehydrogenation of 
4OHT to a quinone methide (Figure 3.1) were performed for one conformation 
each intermediate. Only one conformation was used for these scans and the H9a 
and H9b naming is arbitrary (Figure 3.2). Rigid scans of just one conformation 
may have produced some conformation-dependent differences in the energies of 
H9a and H9b; hence, we used conformations based on the parent’s A 
conformation that were identified, as described above, for each intermediate 
along the dehydrogenation pathway. HF/6-31G*//uB3LYP/6-31G* optimized 
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conformations of dehydrogenation reaction coordinate intermediates at stable 
minima, as determined via frequency analysis, were then subjected to a rigid 
scan of hydrogen CH bonds involved in the dehydrogenation of TAMX 
metabolites in 40 x 0.1 Å steps. Initially, relaxed scans were performed, but these 
were computationally much more intensive and produced spurious results in 
which the hydrogen atom recombined with another part of the molecule. Certain 
bonds that could not be successfully scanned as a stretch from the optimized 
coordinate were performed starting +4.0 Å to the optimized CH bond length of 
interest followed by 40 x (-)0.1 Å step scans to the return to the optimized 
structure geometry. The UB3LYP/6-31G*scans were performed using the 
SCF=QC method, NOSYMM constraints and the MAXCYCLE limit extended to 
1000. 
Substrate charge fitting.  Restrained electrostatic potential  (RESP) 
charges36 were derived using RED-III37 for the optimized geometries and 
molecular electrostatic potential (MEP) computations were performed on multiple 
orientations of four  conformations for 4OHT in both charge states, based on 
atoms C9, O22 and N14 (see Figure 3.2 for atomic numbering). 
Initial P450 loop refinement. For the x-ray structures, (PDB ID: 1TQN24 
and 1W0E23) used for docking and molecular dynamics simulations, missing 
residues in undefined loop regions were identified from the PDB file and added 
with UCSF MODELLER9.938. For each missing loop, five models were built with 
the use of the ‘automodel’ class at the loop refinement level, and ‘refine.fast’ with 
the ‘env.io.hetatm’ set to ‘True’ to include the heme HETATM from the pdb file. 
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The structure with the lowest Modeller Objective Function value was selected for 
further refinement.  
P450 molecular dynamics. MD was performed as described previously29 
except the current simulations were performed with our preliminary heme 
parameters28. Five independent MD simulations were performed for ~40 ns each 
with a different starting structure of the loop-refined (from the independent 
MODELLER loop refinements of) PDB ID: 1TQN24 due to its higher resolution. 
The models were built with the ff99SB force field39 with histidine (δ, ε or doubly 
protonated) states chosen by visualization (residue 27 HID, other histidines HIE). 
Heme parameters (shown in the supporting information) were applied and the 
cysteine-to-iron bond was manually added in tLEAP (residue 415 atom SG to 
residue 473 Fe). Charge was neutralized with chloride ions40 and an additional 
70 Na+ and Cl- ions were added to bring the salt concentration to ~200 mM. The 
models were solvated into a truncated octahedron unit cell with TIP3P water41 
extending at least 12 Å from any of the protein atoms and the positions of the 
ions randomized by randomly swapping with water molecules such that no ions 
were within 4 Å of each other and within 6 Å of the protein. All simulations 
employed AMBER 10.0 or 11.0 with a 9 Å cutoff with an additional 1 Å pairlist 
buffer, automated pairlist builds, the particle mesh Ewald method with default 
settings and a homogeneous long-range correction for the van der Waals 
interactions. MD simulations applied SHAKE42 on all hydrogens and were 
integrated with a 2 fs time step. The models were equilibrated with 500 steps 
each of steepest descent and conjugate gradient minimization with 25.0 kcal/mol-
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Å2 restraints on the protein Cα atoms. Heating with constant volume MD followed 
for 50 ps starting at 100K ramped to 300K over 5000 steps with 25.0 kcal/mol-Å2 
restraints on the Cα atoms. Cycles of 1000 step minimization and 50 ps 
Berendsen-coupled43 constant pressure and temperature MD (0.2 coupling 
times, 300K) followed as before with Cα positional restraints with gradually 
reduced force constants at each step of the cycle of 5.0, 4.0, 3.0, 2.0 and 1.0 
kcal/mol-Å2. Finally, a 500 ps constant pressure MD simulation was performed 
with 0.5 kcal/mol-Å2 positional restraints on the protein Cα atoms, followed by 
production MD with the pressure/temperature coupling times increased to 5.0. 
Each trajectory was determined to have reached steady state with 2D RMSD 
plots. Visual inspection of the 2D RMSD plots was also used to determine the 
most reasonable number of clusters to search for. Analysis was performed with 
the ptraj module of AMBER11, each trajectory was searched for 4 clusters using 
the means clustering algorithm and an average representative structure was 
generated for each cluster in PDB format. From each trajectory, one 
representative structure was selected that represented the largest cluster and 
these were labeled m1-m5. 
QM-heme parameters. All P450 models were prepared as described 
previously29 with the following modifications; all structures were placed into a 
common frame of reference with the Matchmaker utility in UCSF Chimera tools44 
and saved. The existing heme coordinates were modified with QM-derived 
coordinates and force field parameters for the resting high-spin and Compound 
I29 using LEAP in AMBER tools, and an energy minimization (imin = 1) was 
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performed for 1000 steps (maxcyc = 1000) with electrostatics turned off (type = 
'ELEC', value1 = 0.0) and a cut-off of 9.0 Å (cut = 9.0) in implicit solvent was 
performed to relieve any steric clashes. Overlap check was performed with the 
check overlap utility in ptraj, and from this final structure a PDB format coordinate 
file was then generated and prepared for docking with the addition of 
Autodock3.0 parameters and RESP charges to the heme. 
Docking. Four QM energy minimized structures for 4OHT with REDIII-
derived RESP charges calculated using multiple conformation and reorientations 
for the parent molecule were used with each P450 model. The formal charge 
state was denoted as foht- as a neutral and fohtq- with a formal +1 charge due 
to protonation of the amine moiety. Then, 256 independent dockings were 
performed for each of the four conformations, and thus, 1024 dockings for each 
charge state of 4OHT with each P450 model were performed. 
The refinement of the enzyme coordinates involved molecular dynamics 
simulations of the PDB ID: 1TQN24 structure with five independent trajectories, 
and using clustering analysis of all of the structures generated to produce an 
average structure representative of the largest cluster of each trajectory (m1-m5). 
All of the MD-refined structures and the x-ray-based PDB ID: 1W0E23 and 
1TQN24 were then modified with QM-based AMBER compatible heme 
parameters29 and energy minimized to remove any steric clashes. These 
structures were then used with (*-wq) and without (*-00) assignment of atomic 
partial charges and scored using a distance-based scheme from the iron to 
heavy atom at a known SOM. The iron atom was used rather than the catalytic 
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oxygen for both penta- and hexa-coordinate states of the heme so as to 
differentiate the contributions of charges on the heme, sterics due to the 
presence of the catalytic oxygen for the hexa-coordinate Compound I versus the 
penta-coordinate ferric and the contributions of changes in the active site 
architecture to the docking results.  
Docking was performed with AutoDock345 and Autodock tools46 as 
previously published28,29 with the following modifications. The grid box was 
recentered at -21.545, -20.757 and -11.334 displacement from the default center 
assigned by Autogrid3.05 with the dimensions of 68 x 72 x 82 and a resolution of 
0.375 Å in each dimension. Consistent with our previous work, for each of the 
four minima of the substrate 4OHT, 256 independent genetic algorithm runs were 
performed producing a total number of 1024 docked conformations for each 
substrate and heme charge state. This was performed for the two x-ray-based 
(PDB ID: 1TQN and 1W0E) and the 5 MD-refined (m1-m5) P450 models, and for 
each P450 model docking studies were performed with charges assigned or not 
assigned to the heme for each catalytic cycle state. The docking results were 
analyzed using Autodock tools46. The results from each docking were clustered 
consistent with our previous work28. Autodock tools46  was used to perform 
conformational clustering of Autodock345 results with the 2 Å RMSD cutoff for 
conformational similarity of each bin and used the following site of metabolism 
scoring criteria based on the following distances: 
α-OH: Fe-C11 < 8 Å and Fe-R2 > 8 Å 
Dehydrogenation: both Fe-C11 and Fe-R2 < 8 Å 
51 
 
N-demethylation: Fe-C27 or C28 < 8 Å. 
For each repetition of each substrate in each P450 state, the total number 
of poses in every cluster above the 5% cut-off that represented a particular 
reaction mechanism was pooled. A number of ambiguous or nonproductive 
(Non) binding modes were also identified and these were all pooled together.  
For each cluster that had more than 52 representative states (>5% of 
1024 total), the lowest energy conformation was saved in PDB format and further 
analyzed with UCSF CHIMERA44. 
Statistics. Statistical analyses of each reaction mechanism for each 
substrate-P450 state involved a one-way ANOVA and a post-hoc test using the 
Tukey test. Analyses were performed using GraphPad Prism version 5.00 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. 
Channel mapping. CAVER47 was applied to identify the channels present 
within the different P450 structures via the CAVER add-in to PYMOL48. The 
center selection of the P450 was based on the default setting and all structures 
were searched for 10 channels. In each of the runs, only 2-4 distinct channels 
were observed with the remaining channels being redundant to the initial set of 2-
4 channels. Nomenclature was assigned consistent with Cojocaru et al. 200749. 
Active-site mapping. Active sites were mapped with UCSF HOLLOW50 
using a cylinder type of search with a radius 6.5 Å. The axis for each channel 
was found for each structure with CAVER was defined from the activated oxygen 
of the hexa-coordinate heme (O1) to the Cα of the most appropriate residue 
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deemed by visual inspection. The offset to the Cα was also set at 0.0, -1.0 or -2.0 
Å based again on visual inspection.  
Molecular graphics. Images were produced using the UCSF Chimera 
package from the Resource for Biocomputing, Visualization, and Informatics at 
the University of California, San Francisco (supported by NIH P41 RR001081)44 




Materials: 4OHT, NADPH, silver oxide, glutathione (GSH), N-
acetylcysteine (NAC) and raloxifene (internal standard) were obtained from 
Sigma-Aldrich (St. Louis, MO). All other chemicals were of analytical grade and 
obtained at the highest quality commercially available. 
Synthesis of standards of dehydrogenated 4OHT product adducts. 4OHT 
was oxidized using 500 mg silver oxide in 2 ml anhydrous ACN with constant 
stirring at 30°C. Production of 4-hydroxy-tamoxifen quinone methide (4OHT-qm) 
was monitored by UV-vis absorbance at 280 nm. It was determined that 4OHT-
qm had reached a steady-state maximum after ~8 min. Reactions were 
terminated by vacuum filtration of the mixture to remove excess silver oxide and 
purified by flash chromatography, during which the organic solution was added 
drop-wise to ½ volume aqueous phase (100 mM KPi, pH 7.4 with 25 mM NAC) to 
trap the dehydrogenated quinone methides as NAC adducts. These solutions 
were diluted to <5% organic phase and further purified using the Waters Oasis 
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WCX Cation Exchange SPE column. The eluted products were concentrated 
under N2, and reconstituted to a final volume 50 µL MeOH prior to analysis by 
LC/MS. 
 Incubations with 4-hydroxy-tamoxifen. The CYP3A4 wild type and R212A 
mutants were expressed, purified and kinetics characterized as described 
previously51. Incubations were performed as described previously51, except 20 
µM 4-hydroxytamoxifen was used as a substrate, and 5 mM NAC was used 
instead of 4 mM GSH. NADPH (5mM) was used to start the reaction. Reactions 
were allowed to proceed for 12 min at 37ºC and terminated with addition of 200 
µL ice-cold acetonitrile with IS added (RALX 5 µM). The mixtures were then 
vortexed and centrifuged at 21,000xg for 5 min. Excess KPi buffer was added to 
dilute the organic phase to <5%, and products were purified using a Waters 
Oasis WCX SPE cartridge. The MeOH eluate was then concentrated to dryness 
under vacuum with a Savant SVC100 Speed Vac and reconstituted in 50µL 
MeOH for LC-MS analysis. 
LC-MS analysis of 4OHT metabolites. LC-MS analysis of 4OHT 
metabolites was performed as described previously with the following28,52 
modifications: source temperature 385ºC and capillary voltage 10V. 
Chromatography was performed with Phenomenex Jupiter 5µ C4 (150mm x 
2.00mm) reverse-phase column using a mobile phase consisting of Solvent A: 
acetonitrile and Solvent B: 20% MeOH, 0.1% formic acid (v/v/v). The analytical 




4-OHT and its hydroxylated and dehydrogenated metabolites were 
identified as described previously53.  Briefly, 4-OHT was identified as the 
molecular ion at m/z 388.5, with an elution time of 5.6 min. MS2 of this molecular 
ion with activation energy of 34.0% and an isolation width of 3 amu produced a 
major daughter ion at m/z 331. Hydroxylated 4OHT was identified as the 
molecular ion at m/z 404.5, with an elution time of 4.1 min. MS2 of the m/z 404.5 
with an activation energy of 42.0% and an isolation width of 3 amu produced a 
major daughter ion at m/z 386.0 representing the loss of a water. The 
dehydrogenation product 4OHT + NAC was identified as the molecular ion at m/z 
549.0, with an elution time of 4.3 min. MS2 of m/z 549.0 with activation energy of 
20.0% and an isolation width of 5 amu, yielded a major daughter ion with m/z 
386.0 representing the loss of NAC. MS3 fragmentation of the 386.0 daughter ion 
with 42% activation energy and isolation width of 3 amu of this molecular ion 
yielded the major diagnostic ion with m/z 341.1, the diagnostic ion of 4OHT. 
Raloxifene was identified as m/z of 474.5 with an elution time at 4.4 min.  
 
Results 
Substrate geometry optimizations 
The structure activity relationships for tamoxifen have been investigated 
previously in an effort to design the next generation of selective estrogen 
receptor modulators54-59. These studies illustrate the complex interplay of 
interactions with various estrogen receptors and other targets showing how small 
differences in the chemical structure can alter the pharmacological activity60.  
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Early theoretical investigations at lower levels of theory had also provided 
insights into the complex conformational landscape produced by the central 
alkene covalently bound to three aromatic rings, which could occupy multiple 
minima61,62.  However, recent investigations at HF and B3LYP levels of theory 
revealed one minima existed which was in agreement with experimental x-ray 
data63. Energy minimizations at the HF/6-31G* level – the conventional level of 
theory applied for molecular mechanical force field parameterization compatible 
with the nonpolarizable AMBER-based pairwise additive ff9X force fields that 
produce a slight and beneficial overpolarization - identified multiple minima within 
~2 kcal/mol (Table 3.1 and Figure 3.3). The major difference differences in the 
optimized geometries at the HF/6-31G* level involved two sites: 1) the orientation 
of the aromatic rings and ethyl group attached via a central double bond from C7 
to C8, which compose the central ring system; and 2) the oxy-methyl-amine  
(MTOXY) ‘tail’ composed of atoms O11, C12, C13, N14, C15 and C16 (refer to 
Figure 3.2 for nomenclature), which adopted one of two conformations (Table 
3.1).  The differences with the ring system (dihedral angle ψ1-3) relate to different 
‘propellering’ in one of two directions, and the ethyl group is oriented with C10 
above or below the plane defined by the central carbons (C1, C7, C8, C9, C17 
and C23).  
Optimizations at the B3LYP/6-31G* level did not show the same difference 
in orientation of the MTOXY tail. Scans of ψMTOXY at HF/6-31G* and B3LYP/6-
31G* level indicate that the minima observed at the HF level at ~87º is not 
observed at the B3LYP level. The B3LYP/6-31G* structures shared all the other 
56 
 
trends and showed similar energy differences. Since structures derived at the 
B3LYP-level of theory have been shown to be in good agreement with 
experimental structures63, the DFT-based conformations were used for further 
modeling. The differences between these four geometries are shown qualitatively 
in Figure 3.3. Of the four conformations, denoted A-D, A and C share similar 
orientations of the ring systems as do B and D. The main differences between 
these two pairs relate to the orientation of the ethyl group at C9 and C10. 
 
Mulliken population analysis of atomic spin densities for 4OHT 
 open-shell dehydrogenation reaction intermediates 
 
In an attempt to identify sites of metabolism and hydrogen abstraction, 
atomic spin densities of open shell species were calculated to assess the relative 
probabilities of unpaired electrons at specific sites on 4OHT. In addition, gas-
phase ab initio quantum mechanics calculations probed the sequence of 
hydrogen abstraction involved in dehydrogenation of 4OHT. Previous gas-phase 
quantum mechanics based studies of the desaturation of a radical clock 
substrate and a truncated thiolate model of the heme/Compound I concluded that 
“the oxidase-dehydrogenase mixed activity occurs from the cationic intermediate 
species and requires electro-steric inhibition of the rebound process”27. Based on 
the hypothesis that the mixed activity occurs with the cationic intermediate 
species, we evaluated the applicability of this approach for identifying SOM of 
dehydrogenation reactions that involve two distinct SOM, specifically C9 and O29 
for 4OHT, as opposed to other P450-catalyzed reactions that commonly involve 
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one hydroxylation or neighboring atomic centers such as epoxidation 19. Also, 
since the major CYP3A4 metabolites of 4OHT have been identified 
experimentally as α-hydroxylation at C9, and N-demethylation at C15 and C16, 
and the major CYP2B6 4OHT hydroxylated metabolite at C2630, we also 
evaluated atomic spin densities at these sites.  
Gas-phase reaction coordinates for 4OHT dehydrogenation are shown in 
Figure 3.4 and for all four conformations of the first cationic species formed, we 
examined the Mulliken atomic spin densities to see if this approach would identify 
the site of the first hydrogen abstraction. The highest spin densities were 
observed at C8, which is not a commonly observed P450 SOM, and C26, the 
observed SOM for 4’-hydroxylation by both CYP3A4 (minor metabolite) and 
CYP2B6 (major metabolite)30. However, spin densities did not predict metabolism 
at C9 or at any of the carbon atoms bonded to N14, the SOM for the major 
metabolites produced by CYP3A4 from 4OHT. Mulliken atomic spin densities for 
all three intermediate neutral radical species were also examined for the single 
lowest energy conformation (A), to determine if these might identify the site of the 
second hydrogen atom abstraction in the dehydrogenation of 4OHT. The 
Mulliken atomic spin densities remained high at the site of hydrogen atom 
abstraction for each species, and at C7 for the radicals formed from aliphathic 
hydrogen abstraction. Thus, the Mulliken atomic spin densities from gas-phase 
QM calculations at the 6-31G* level of theory for the open-shell species formed 
along the putative dehydrogenation reaction coordinate do not identify the SOM 
for the CYP3A4 metabolism of 4OHT, except for the minor product 4’-hydroxy-
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tamoxifen. A priori knowledge is therefore required to identify the two 
dehydrogenation SOM of 4OHT by CYP3A4.  
 
Investigation of the sequence of hydrogen atom abstraction 
Since the SOM for dehydrogenation with gas-phase calculations of the 
substrate alone were not useful, a priori knowledge of the SOM resulting in the 
formation of the desaturated quinone methide species identified experimentally31 
was used for further analysis. We selected conformation (A), one of the two 
lowest energy conformations, to perform analysis of the energy differences of all 
of the stable species formed along each putative reaction pathway for hydrogen 
abstraction (Figure 3.4).  For this study, we utilized two distinct approaches to 
determine the order of hydrogen abstraction. Since it had been previously 
proposed that the formation of a stable cation was likely a key factor required to 
undergo dehydrogenation, approach 1 investigated the stability, relative energies 
and electron affinities of the putative intermediates determined to be involved in 
the formation of 4OHT quinone methide31, while approach 2 calculated the bond 
dissociation energies (BDE) of these bonds.  
Approach 1: Stability, relative energies and electron affinities of 
intermediates along putative l pathways of hydrogen atom abstraction for the 
formation of quinone methides from 4OHT. We performed geometry 
optimizations and frequency analyses for all putative gas-phase intermediates 
that could be formed from abstraction of the three hydrogen atoms putatively 
involved along the dehydrogenation reaction coordinate (Figure 3.4). All species 
59 
 
were determined to be at stable minima due to the absence of negative 
frequencies. The cation 1 intermediate is an open-shell doublet with a +1 charge 
formed from the parent. The subsequent radical intermediates can be formed 
from the abstraction of H29a, H9a or H9b, resulting in neutral open-shell 
doublets. The second cation 2 intermediate can be formed from any of the 
putative neutral radical intermediate species, has a +1 charge and is a singlet. 
The parent and product species are neutral closed shell systems. A summary of 
the difference in the sum of electronic and the thermal free energies relative to 
the lowest energy equivalent intermediate is given for each species with the 
corresponding electron affinity (Figure 3.4).  
The largest observed energy difference was for the formation of the 
second cationic species from the abstraction of H29a which was ~30 kcal/mol 
higher in energy than either of the second cationic species formed from the initial 
abstraction of either allylic hydrogen atom (H9a or H9b). This species also has a 
greater electron affinity than either of the two cation 2 equivalents or of cation 1. 
These data suggest that dehydrogenation would be least favored to proceed via 
an initial hydrogen abstraction from the hydroxyl group based on the energies of 
the intermediates along the putative dehydrogenation pathways involving C9 and 
O29 explored here. 
Approach 2: Bond dissociation energies (BDE). The BDE for the parent 
and the first cationic species formed show that, for conformation A, the H9a 
abstraction was the lowest energy (Figure 3.5). The BDE for the three neutral 
radical intermediate species and the second cationic intermediate (Cation 2) 
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indicate that the hydroxyl bond (H29a) is the lowest in energy for the second 
hydrogen atom abstraction. These results together suggest that the 
dehydrogenation of 4OHT likely proceeds with the abstraction of the allylic H9a 
followed by the abstraction of the hydroxyl H29a. 
This gas-phase method provides a physical basis to more quantitatively 
score docking results to accurately identify the site and order of metabolism. 
These data suggest that 4OHT likely undergoes sequential abstraction of 
hydrogen atoms beginning with the aliphatic hydrogen. This underscores the 
importance of sampling and identification of all of the minima available at 
physiological temperatures. Furthermore, the QM-based reaction coordinate 
pathway energetic analysis and BDE provide a physical basis to support the 




  Molecular docking was performed to investigate putative binding modes 
of the substrates in the active site of CYP3A4. To provide a more realistic 
sampling of active site geometries beyond that shown in the available crystal 
structures, molecular dynamics simulations were employed. The use of 
ensembles of representative configurations of enzyme-substrate structures 
sampled with modern MD simulation protocols when used with computationally 
affordable tools such as docking holds great promise for structure-based 
prediction metabolism of new chemical entities64,65. In spite of sampling 
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limitations and force field inaccuracies66, MD simulations can fold small proteins67 
and accurately model protein-ligand interactions using modern simulation 
protocols and balanced force field treatments68.  
To confirm that the energy barriers between the minima were low enough 
for the minima to be thermally accessible at physiological temperature, scans of  
all the ψ* dihedral angles as defined in Figure 3.1 were performed. The results of 
these scans indicated that the energy barriers would indeed allow all of these 
minima to be occupied at physiological temperatures. Therefore, docking was 
performed with all four representative structures, and the results from all four 
dockings were combined. 
Single docking runs only provide a “snap-shot” of enzyme- substrate 
interactions. However, this allows docking programs (e.g. Autodock3) that treat 
the coordinates for the biomolecule as static and use a united atom treatment to 
provide for fast sampling of the search space. However, identifying one pose out 
of many by visually inspecting the docking results can be time consuming, and 
subject to issues of signal-to-noise, which may not provide statistically significant 
results. A commonly applied metric for identifying potential SOM after docking is 
the use of distance-based scoring schemes, such as sites within 5 Å of the heme 
oxygen12,20,51,69. Autodock345 uses a united atom treatment and a static protein 
model. Moreover, since our heme models now include the catalytic oxygen atom 
in the hexa-coordinate heme state, the lowest energy docked structure within a 
family of similar poses may not necessarily correspond to the pose most 
amenable to catalysis. Therefore, we loosened the distance criteria for scoring 
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the SOM for the lowest energy conformation representative of each cluster of 
Autodock3 results. Specifically, a cutoff < 8 Å from the iron atom to the heavy 
atom representing the SOM was used for metabolism involving a single SOM, 
e.g. hydroxylation and N-demethylation, and for dehydrogenation, one of the two 
iron-to-SOM distances should be < 5.5 Å and the iron to the second SOM 
distance should be < 8 Å. Visual inspection of productive clusters showed that 
within each cluster/bin, structures could be found where the corresponding iron-
SOM distance was < 5 Å.  
We improved the sampling by performing multiple independent docking 
runs so as to allow for statistical analysis of the results. We also imposed an 
arbitrary signal-to-noise cutoff by only evaluating clusters which had >5% of the 
total population. In most cases, this reduced the number of clusters analyzed per 
1024 docking runs to <10 clusters. All of the docking studies were repeated three 
times, independently, and analyzed for statistically significant differences for 
each reaction mechanism. 
Preliminary docking studies using x-ray structures of CYP3A4 (PDB ID: 
1W0E23 and 1TQN24) with a single MM2 energy-minimized structure of 4OHT 
with Gasteiger charges assigned, no charge assignment to the heme atoms, 
consistent with our earlier work with RALX, did not identify binding modes that 
supported the observed metabolism of 4OHT. Conversely, docking studies with 
multiple conformations of 4OHT with the PDB ID:1W0E-based structure modified 
with QM-based heme parameters (1w0e-ic6-00/wq and 1w0e-cpdi-00/wq) 
identified a number of binding modes supportive of α-hydroxylation (α-OH) and 
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N-demethylation (NdM) with the penta-coordinate heme (Figure 3.6). Docking 
with this same P450 structure with the hexa-coordinate heme parameters for 
Compound I identified a binding mode supportive of both α-hydroxylation and 
dehydrogenation (dH1). The association of this binding mode with a specific 
reaction mechanism is ambiguous since no specific residues capable of 
producing the required steric hindrance to inhibit the hydroxyl rebound 
mechanism are observed. Interestingly, the number of configurations supportive 
of NdM were increased with the presence of the catalytic oxygen without atomic 
partial charges. This result suggests that, with this enzyme model the steric effect 
from the presence of the catalytic oxygen is decreased with the assignment of 
atomic partial charges that causes a change in the orientation of the flexible 
MTOXY moiety. Also, the number of non-productive modes in the major clusters 
significantly decreased with the use of the hexa-coordinate heme parameters, 
indicating that the presence of the catalytic oxygen atom has a greater steric 
contribution for 4OHT with this x-ray model.   
A similar approach with the PDB ID: 1TQN-based structure modified with 
QM-based heme parameters (1tqn-ic6-00/wq and 1tqn-cpdi-00/wq), docking 
studies identified mostly non-productive modes and 1 productive mode 
supportive of α-hydroxylation (Figure 3.6).  
To incorporate flexibility and dynamics in the active site structures, five 
different MD trajectories of the starting 1TQN structure were also evaluated. To 
choose representative structures for docking, clustering of the structures 
sampled at 1 ps-intervals by RMSD similarity for each trajectory was performed. 
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The average structure from the largest cluster was chosen for docking in each of 
the five trajectories. To remove artifacts from averaging, the structure was first 
minimized with the electrostatic interactions turned off to remove steric clashes. 
Docking studies with the MD-based structure m2 modified with QM-based 
heme parameters (m2-ic6-00/wq and m2-cpdi-00/wq) also predicted α-OH, NdM 
as well as an alternate binding mode supportive of dehydrogenation (dH2). This 
binding mode suggested R212 as a single residue that could potentially produce 
electro-steric inhibition of the hydroxyl-rebound mechanism leading to 
dehydrogenation. The number of poses in the dH2 binding mode also 
significantly increased with the inclusion of hexa-coordinate Compound I 
coordinates and atomic partial charges. For this structure, the number of non-
productive binding modes in the largest cluster also significantly decreased with 
the incorporation of hexa-coordinate Compound I coordinates. 
 
Analysis of QM-based heme parameters and substrate  
charge state in docking 
 
Inclusion of the heme charge and coordinate parameters, and alternate 
charge state for the substrate did not produce a significant “across the board” 
improvement for modeling 4OHT-CYP3A4 interactions with 1W0E, 1TQN or the 
MD refined models. Furthermore, significant model-specific differences were 
observed in binding modes supporting different reaction mechanisms, except α-
OH. To ensure that the substrate charge state did not alter the docking results, 
these studies were repeated with charged 4OHT. Similar results were obtained 
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with neutral, and +1 4OHT with respect to identifying SOM and various reaction 
mechanisms. Significant differences for the same model, with and without 
charges, were also observed for a few dockings, but no significant improvement 
based on the charge state of 4OHT or heme parameters was observed across all 
CYP3A4 models. However, it should be noted that inclusion of the hexa-
coordinate state never eliminated a binding mode identifying the SOM for any 
structure tested. In fact, inclusion of these coordinates was required to identify 
the dH1 and dH2 binding modes. 
 
4OHT binding modes and CYP3A4 conformational dynamics 
and active site architecture 
 
For CYP3A4 models that produced binding modes supportive of 
dehydrogenation, two modes were observed, labeled dH1 and dH2. The dH1 
binding mode was similar in orientation to the binding mode that supported α-OH, 
except with 4OHT “flipped over”, thus placing O29 in a position within hydrogen 
abstraction distance to the heme (Figure 3.7). However, with the dH1, no 
residues were observed to intervene between 4OHT and the catalytic center of 
the heme to provide the necessary steric inhibition of the rebound process. This 
makes interpretation of dehydrogenation versus hydroxylation ambiguous using 
this type of MM-based approach. In contrast, the dH2 binding mode clearly 
positioned Arg212 in an orientation that imposed steric and potentially electro-
static inhibition of the rebound process. This was only observed with the m2 
model. Further, the m2-based dH2 pose showed significant improvement in the 
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results predicting the involvement of the dehydrogenation with the inclusion of 
the QM-based heme charges. 
 
Ingress, egress and solvent channels 
Examination of the binding modes within the context of the active site of 
the MD-refined m2-cpdi and w0e-cpdi models show that for 4OHT, the opening 
and closing of the ingress and egress channel 4 provides a space for the 
substrate with respect to the catalytic site of the enzyme (Figure 3.7). In the m2 
structure, channels 2b, 4 and S were determined to be open. The dH2 binding 
mode is only possible with the opening of channel 4, in such a manner so as to 
allow 4OHT to partially occupy it. The other major reaction mechanisms (i.e. α-
OH, dH1 and NdM), are supported by binding modes that allow 4OHT to occupy 
a region of the active-site directly above the heme, that among the models 
tested, appears to be less malleable. 
Table 3.2 shows the channels that were identified for each model and the 
reaction mechanisms determined to be supported by our scoring scheme.  All of 
the channels present in the MD-refined structures are present in published 
CYP3A4 x-ray structures, but in different combinations, including channel 4, 
which is observed in another x-ray structure. 
By comparing structure specific channels and binding modes (Table 3.2), 
it can be clearly seen that there is no one-to-one relation between channel 
opening and closing and substrate binding. For structures that do have channel 4 
open, specifically m2, m3, m5 and PDB ID: 2V0M, the orientation and structure 
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of channel 4 was examined (Figure 3.8). For all four structures different volumes 
and paths defined for channel 4 were observed. The positioning of Arg212 
toward the heme is similar for m2, m3 and m5, but for 2V0M8, the Arg212 is 
oriented away from the heme (Figure 3.8). This would suggest that the use of this 
model would not have implicated the potential role of this residue in 
dehydrogenation. Therefore, both the channel 4 open state and Arg212 oriented 
toward the heme are required for a binding mode that supports dehydrogenation 
of 4OHT.  
Analysis of the representative structures used here identifies that different 
regions of the CYP3A4 active site are perturbed by the open or closed state of 
ingress and egress channels to different degrees. These more malleable regions 
appear to have multiple states available to them. Thus, we recommend future 
docking studies of CYP3A4 with larger substrates, such as 4OHT, to include 
multiple structures with multiple combinations of open channels. In fact, using a 
number of CYP3A4 structures with different combinations of open channels may 
prove to be an important metric of achieving adequate sampling for identifying 
modes supportive of different SOM and P450-catalyzed reaction mechanisms.  
 
Incubations and liquid-chromatography mass-spectroscopy 
analysis (LC-MS) 
 
LC-MS analysis of incubations with CYP3A4 and the CYP3A4-R212A 
mutant showed a dramatically altered rate of dehydrogenation versus 
oxygenation, adding support to the results from the modeling studies. LC-MS 
semiquantitative analysis of incubations of 4OHT with CYP3A4 wild-type and 
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CYP3A4-R212A produced both hydroxylated and dehydrogenated metabolites. 
However, CYP3A4-R212A produced significantly less dehydrogenated product 
(p=0.016), while the amount of hydroxylated metabolite was essentially 
unalterered (p=0.677) (Figure 3.9).   
 
Conclusions 
The dH2 binding mode correctly implicated the potential role of Arg212 in 
the steric hindrance required to inhibit the rebound process of the 
dehydrogenation of 4OHT.  Arg212 could possibly also be contributing some type 
of electrostatic repulsion of the cationic intermediate formed during the 
dehydrogenation reaction coordinate. Our docking results show that population of 
the dH2 binding pose is sensitive to both inclusion of atomic partial charges and 
Compound I coordinates. Thus, Arg212 may provide both steric and electrostatic 
hindrance of the hydroxyl rebound process. However, the possible contributions 
from the dH1 mode, with inhibition of the rebound process due to thermodynamic 
fluctuations of the active site architecture as a whole, cannot be ruled out. Nor 
can we rule out the possibility that other biologically relevant binding modes may 
exist that we have yet not identified.  
Interestingly, the key residue involved in the dehydrogenation of 4OHT is 
different than that identified in previous work with RALX, suggesting that these 
two SERMs have diverse conformational landscapes in the CYP3A4 active-site; 
even though they are able to bind the ER in the same manner, their P450 
metabolism requires very different binding modes.  
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QM-based energy minimizations identified multiple conformational minima 
for 4OHT that are likely thermally accessible at physiological temperatures. 
Therefore, performing MM-based studies requires sampling from all of these 
minima. The ab initio methods used here did not unambiguously identify the 
dehydrogenation SOM and a priori knowledge was required to do so. However, 
QM-based methods did consistently support the energetically favored sequence 
of hydrogen atom abstraction and provided a physical basis for the docking 
scoring scheme used here. 
MD simulations of x-ray structure supportive of only one productive 
binding mode (PDB ID: 1TQN) produced models with ingress and egress 
channels observed to be present in other CYP3A4 experimental structures but in 
different combinations. These models, when used with computationally 
inexpensive docking tools, identified binding modes supportive of the entire 
metabolism of 4OHT by the most promiscuous and biomedically relevant hepatic 
P450, CYP3A4.  One unique enzyme-substrate configuration was identified in a 
MD-based model that involved the potential interaction of a single residue, 
Arg212, and was supportive of the dehydrogenation reaction. Enzymatic 
incubations with a R212A mutant of CYP3A4 confirmed the role of this residue in 
the dehydrogenation of 4OHT. Use of these different models with QM-based 
heme parameters for the heme and charge states for 4OHT showed that for this 
hydrophobic substrate, the contribution of atomic partial charges was not as 
important as for RALX. 
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Comparison of these theoretical enzyme-substrate configurations have 
identified regions of the enzyme active site that differ in plasticity, and different 
binding modes supportive of the same reaction mechanisms.  We postulate that 
the difficulties in identifying the SOM and PRM for CYP3A4 are related to the 
binding modes within the active-site. Depending on the size, rigidity and polarity 
of the substrate, multiple binding modes may be available supportive of the same 
PRM. This is further complicated by the fact that certain regions of the CYP3A4 
active site appear to be more malleable than others. Thus, for some substrates, 
multiple binding modes may be available, and some of these may exist within 
these plastic regions which cannot be modeled using x-ray data alone. We 
speculate that these plastic regions, particularly those surrounding channel 4, 
which is formed with the long insertion in the F-G loop, unique to mammalian 
P4505, may play an important part in the ability of a number of classes of P450 
enzymes ability to accommodate chemically diverse substrates. Furthermore, the 
contribution of the cavities formed by the channels may play a more important 
role than that of individual residues for binding of more flexible and nonpolar 
substrates.  
Based on our findings, we recommend that future computational CYP3A4 
metabolism studies identify all the available minima for the substrate and verify 
that the interconversion between these minima is thermally possible so as to 
provide adequate sampling. We recommend that docking studies be performed 
with the penta- and hexa- coordinates, since inclusion of these parameters has 
been shown to help increase the observed number of productive binding-modes 
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for molecules with both rigid and flexible cores, albeit in different manners. 
Regarding models of the enzyme, it is recommended that in the refinement of 
existing experimental models, adequate sampling also be performed and 
considered when attempting to identify different states of the enzyme in regards 
to the opening and closing of channels. This is especially important for larger, 
more flexible substrate or ligand molecules that can occupy these volumes 
adjacent to the active-site. To identify binding modes supportive of the entire 
metabolism of CYP3A4 substrates, including minor reaction pathways such as 
dehydrogenation, that produce unstable and reactive metabolites, it is important 
to adequately sample the conformational space of the enzyme.   
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Figure 3.1: Scheme for one putative pathway of P450 mediated bioactivation of 
tamoxifen (TAMX) to estrogen-receptor (ER) active 4-hydroxy-tamoxifen via 
P450-catalyzed hydroxylation, followed by conversion to 4-hydroxy-tamoxifen 
quinone methide (4OHT-qm) which then forms an adduct with a biomolecule (X) 





















































Figure 3.3: Four (A-D) different energy minimized geometries of 4-hydroxy 

























Figure 3.4:  Scheme for alternate hydrogen abstraction pathways for 4OHT 
intermediates along the dehydrogenation reaction coordinate. Differences in the 
sum of electronic and thermal free energies for each species are shown relative 
to that of the lowest energy equivalent intermediate in black. Electron affinities 
are shown where applicable as relative energy to previous neutral intermediate in 

























Figure 3.5: Final bond dissociation energies of carbon-hydrogen and oxygen-
hydrogen bonds involved in the dehydrogenation of 4OHT at 4 Å extension for all 
intermediates on the dehydrogenation reaction coordinate: (A) first hydrogen 
abstraction, (B) second hydrogen abstraction. The legend indicates the hydrogen 





Figure 3.6: Ratio of Autodock3 binding modes supportive of observed 
metabolism of 4-hydroxy-tamoxifen reaction mechanisms alpha-hydroxylation (α-
OH) dehydrogenation modes 1 and 2 (dH1 & dH2), N-demethylation (NdM) and 
nonproductive and/or ambiguous modes (Non) with CYP3A4 experimentally 
derived x-ray (A) PDB ID: 1W0E, (B) PDB ID: 1TQN and (C) molecular dynamics 
refined m2 refined with quantum mechanics based heme parameters for resting 
high-spin (ic6) and Compound-I (cpdi) with (wq) and without (00) RESP charges 
assigned to the heme. Statistically significant differences are indicated with 










































































Figure 3.7: Active site and major channels (red grid) for structure m2-cpdi (cyan) 
and w0e-cpdi (yellow) shown with orientation of representative poses scored for 
different reaction mechanisms (A) α-hydroxylation [αOH], (B) dehydrogenation 
[dH2], (C) N-demethylation [NdM] and (D) dehydrogenation [dH1]. Volumes 
defining active-site and ingress/egress channels are shown as red mesh and 
labeled S (solvent), 2b, 2e and 4 channels. The 1w0e-cpdi and m2-cpdi model 
are shown at slightly different angles, and the peptide backbone in the 
foreground for all pictures has been hidden to allow the differences in the 
structure and orientation of channels and substrate to be seen more clearly. 














Figure 3.8: Differences in channel 4 and position of ARG212. (A) Volume and 
placement of channel 4 as defined by CAVER shown as a surface for each 
model m2 (lime green), m3 (purple), m5 (orange) and 2V0M (yellow). The 
CYP3A4 backbone is shown for the m2 model as a grey ribbon, the F-G loop 
(which includes the F’ and G’ helices) is shown in red.  (B) Position of ARG212 
and heme for m2 (lime green), m3 (purple), m5 (orange) and 2V0M (yellow) 
shown in reference to docked conformation of 4OHT (cyan) in dH2 pose. 
Hydrogen atoms have been hidden for clarity. Neighboring residues to ARG212 
are shown only as ribbon for the back bone and atoms hidden also for clarity. 
















Figure 3.9: 4OHT relative dehydrogenation and hydroxylation 4OHT products of 
Wild-Type (WT) versus Mutant (R212A) CYP3A4. Statistical significance 














B3LYP/6-31G* ψETHYL ψ1 ψ2 ψ3 ψMTOXY ΔZPE ΔG
A 115.7 127.9 134.7 -56.6 1.3 0.1 0.2
B 76.1 -136.5 -137.7 63.3 1.5 1.9 2.4
C -76.1 136.0 137.1 -63.0 1.5 1.8 2.1
D -115.4 -127.8 -134.5 56.5 1.0 0.0 0.0
HF/6-31G* ψETHYL ψ1 ψ2 ψ3 ψMTOXY ΔZPE ΔG
A 114.0 119.4 127.3 -64.1 1.8 0.0 0.0
B 81.2 -119.8 -127.5 69.1 87.3 3.2 1.9
C -81.2 119.7 128.4 -68.8 1.8 2.0 1.5
D -113.8 -119.5 -126.4 64.6 87.4 1.1 0.4
Table 3.1: Key dihedral angles of ψA-C, ETHYL & MTOXY and differences in zero-point 
energies (ΔZPE) and sum of electronic and free energies (ΔG) for four 
nonredundant optimized geometries of 4-hydroxy-tamoxifen. Conformations 
labeled (A-D) at results from  calculations at (i) HF/6-31G*, (ii) B3LYP/6-31G* 
levels of theory.  Differences in energy are shown in units of kcal/mol. Dihedral 




















Table 3.2: Identification and classification of (i) ingress/egress channels and (ii) 
binding modes supportive of different reaction mechanisms for refined molecular 












model # channel 2a 2b 2e 4 5 Solvent 
m1-cpdi 2 5 S
m2-cpdi 3 2b 4 S
m3-cpdi 4 2b 2e 4 S
m4-cpdi 3 2b 5 S
m5-cpdi 4 2a 2b 2e 4
1w0e-cpdi 4 2b 2e 5 S
1tqn-cpdi 3 2a 2e S
model # productive modes α-OH dH1 dH2 NdM Non
m1-cpdi 2 NdM Non
m2-cpdi 3 α-OH dH2 NdM Non
m3-cpdi 1 Non
m4-cpdi 1 NdM Non
m5-cpdi 2 α-OH dH1 NdM Non
1w0e-cpdi 3 α-OH dH1 NdM Non







P450-mediated drug metabolism continues to be an area of intensive 
research even four decades after the discovery of this class of enzymes. The 
accumulating experimental evidence continues to provide insights into the 
functional diversity of these enzymes. Current experimental methods for 
structural studies of P450s, such as x-ray crystallography, only provide snap-
shots of conformational states of the enzyme. For the P450s that have a number 
of x-ray structures available bound to chemically diverse ligands and substrates, 
the data provide insight into the potential plasticity of the active-sites of these 
enzymes. From these static snap-shots, the thermodynamic contributions to the 
structure of the enzyme cannot be determined. However, these structures do 
provide a framework of experimental evidence for the application for 
computational modeling techniques to predict the conformational dynamics of 
P450s. Improved models of P450 structure based on existing x-ray structures but 
accounting for thermodynamic contributions have been shown here to be 
important for accurately predicting drug metabolism. Thus, the application of 
computational tools for biophysical analysis in this manner can not only provide 
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insight into the basic biochemistry of enzyme-substrate interactions, but also 
have a beneficial impact on human health overall.  
Recent work on P450 flexibility with molecular dynamics has identified the 
importance of the ingress and egress channels1. A number of MD-based studies 
in the absence2,3 and presence4 of the lipid bilayer using small substrates have 
shown that these channels can accommodate the movement of compounds to 
and from the active-site. Furthermore, data from spectroscopic analyses at 
normal and high pressures would indicate that family-specific differences exist in 
the malleability of the P450 active-site5. Unfortunately, even the most 
sophisticated current computational tools6-9 for prediction of drug metabolism do 
not account for the fluctuations of the protein backbone nor the changes in the 
structure or the electronic state of the heme during the P450 catalytic cycle.  
Based on the findings presented in this dissertation, both the QM-based 
parameters for changes in the heme during the P450 catalytic cycle, and the 
MM-based modeling of the thermodynamic fluctuations of the CYP3A4 active 
site, are required criteria to accurately model enzyme-substrate interactions. 
Each of these factors has been shown to play an important role in identifying 
binding modes that are supportive of the multiple pathways of the metabolism of 
4OHT and raloxifene. In the case of raloxifene, the assignment of atomic partial 
charges to the heme increased the accuracy of our models. However, in the case 
of 4OHT, less dramatic effect due purely to the assignment of atomic partial 
charges was observed. This may have been due, in part, to the more polar and 
rigid 2-(4-hydroxyphenyl)-benzothiophen-6-ol core of raloxifene. This rigid core 
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structure may have induced a molecular reorientation which was more 
susceptible to local charge-charge interactions. It was shown that for 4OHT, a 
molecule with a more flexible core, the accurate modeling of the conformational 
dynamics of the enzyme structure was also important for identifying the binding 
modes suggestive of its entire observed metabolism. Accurately identifying 
binding modes supportive of the entire metabolism of novel compounds is 
important since minor pathways of metabolite production can be responsible for 
toxicities10. Unfortunately, most of the current tools that are used for predicting 
drug metabolism are only successful in identifying the major metabolite of the 
more substrate-selective hepatic drug metabolizing P450s, such as CYP2D66,9.  
Our work with 4OHT and CYP3A4 shows that the active-site of CYP3A4 
may differ in plasticity in specific key regions. Specifically, a binding mode was 
identified and experimentally confirmed for the dehydrogenation of 4OHT that 
involved a channel formed between the F’- and G’-helices in the F-G loop. This 
loop feature is unique to mammalian P450s11, and this finding suggests that 
depending on the size, flexibility and polarity of the substrate, the binding mode 
supportive of catalysis may be dependent on reshaping of key regions of active 
site. Furthermore, it is important to stress that this feature of CYP3A4 was only 
observed through analysis of multiple MD trajectories of >40ns. Currently, most 
MD simulations use only one trajectory of shorter duration2,9 to model the 
conformational dynamics of P450s. This multiple trajectory approach produced 
models of CYP3A4 that were then used with relatively unsophisticated docking 
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tools to identify the entire metabolism of 4OHT by CYP3A4, including binding 
modes supportive of its metabolism to a reactive quinone methide species.  
These findings raise an intriguing question: Can the available 
computational tools now correctly identify the conformational dynamics of hepatic 
drug metabolizing enzymes? Based on the success of the approach developed 
and exemplified herein with raloxifene, 4OHT and CYP3A4, further investigation 
of this flexible characteristic of the major classes of hepatic P450s, CYP3A4, 
CYP2D6, CYP2E1, CYP2A6 and CYP1A2, with and without substrates, would be 
of great interest. These studies could identify regions of differing plasticity in the 
different P450 active sites. These data could then be used with model substrates 
to determine to what degree the plasticity of the active site played a role for 
different substrates and P450s. This new understanding would facilitate the 
development of classification scheme for P450s and their substrates. This 
classification scheme would determine how extensive a computational approach 
would be required to accurately determine metabolism of novel compounds as 
well as provide models that could be used with computationally affordable tools 
to rapidly screen chemical libraries. 
The results from future research would not only be of benefit for drug-
metabolism and safety but would also be of long-term benefit to a number of 
other areas of biomedical sciences. Experimental approaches that use site-
directed mutagenesis, or directed evolution in altering P450 function, including 
application such as biosynthesis, rational drug-design targeting nonhepatic P450 
such as for the treatment of prostate cancer, and P450 structural refinement 
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methods used in spectroscopy could all benefit from the identification of flexible 
motifs in the P450 active-site.  
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